Differential gene expression signature (Ladon report)
Risk or response signature built by selecting genes associated with the outcome and combining their standardised expression, with signature size chosen by cross-validation on training data.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for Differential gene expression signature (Ladon report). Fields the record does not carry are marked not recorded.
Evaluated Checkpoint: As described in the Ladon technical report
Evaluations and results
7 evaluations · 7 results. Different protocols are not a single leaderboard.
Sorted by AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Protocol and dataset | AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials) | Concordance index (Uno's C-index, overall survival, mean over six trials weighted by evaluated patients; training pool TCGA plus non-trial cohorts plus other trials (largest pool, about 18k samples)) | Concordance index (Uno's C-index, survival endpoint not specified beyond 'survival', equal mean over six CPTAC target cancers, predictor fitted on TCGA) | Concordance index (Uno's C-index, survival endpoint not specified beyond 'survival', equal mean over six TCGA target cancers, predictor fitted on CPTAC) | Concordance index (Uno's C-index, survival endpoint not specified beyond 'survival', pan-cancer (pairs across cancers counted), equal mean of the TCGA to CPTAC and CPTAC to TCGA transfers) | Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials) | Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials) |
|---|---|---|---|---|---|---|---|---|
| Differential gene expression signature (Ladon report)Evaluation | Held-out trials, immunotherapy response AUROC, equal mean over six trials, Immunotherapy arms of six held-out trials with evaluable response | 0.633 | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Differential gene expression signature (Ladon report)Evaluation | Survival transfer CPTAC to TCGA, mean Uno C-index over six cancers, TCGA six-cancer transfer target set (2,461 patients) | Not reported | Not reported | Not reported | 0.6 | Not reported | Not reported | Not reported |
| Differential gene expression signature (Ladon report)Evaluation | Survival transfer TCGA and CPTAC, pan-cancer Uno C-index, mean of two directions, TCGA and CPTAC transfer target sets combined (pan-cancer panel) | Not reported | Not reported | Not reported | Not reported | 0.59 | Not reported | Not reported |
| Differential gene expression signature (Ladon report)Evaluation | Survival transfer TCGA to CPTAC, mean Uno C-index over six cancers, CPTAC six-cancer transfer target set (1,128 patients) | Not reported | Not reported | 0.63 | Not reported | Not reported | Not reported | Not reported |
| Differential gene expression signature (Ladon report)Evaluation | Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials, Six held-out trials with overall survival | Not reported | Not reported | Not reported | Not reported | Not reported | 1.52 | Not reported |
| Differential gene expression signature (Ladon report)Evaluation | Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials, Three held-out trials with progression-free survival | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | 1.74 |
| Differential gene expression signature (Ladon report)Evaluation | Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool, Six held-out trials with overall survival | Not reported | 0.595 | Not reported | Not reported | Not reported | Not reported | Not reported |
All 7 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Use this method
How it works, versions and access
Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this method. Consult the linked sources and evaluation records below.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Original source · Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ladon-20261115-method-dge-signature.
Source locator: Page 11, Comparators table, row 'DGE'; page 16 for the response version
Related records
- system: Differential gene expression, survival transfer CPTAC to TCGA, Uno C-index
- system: Differential gene expression, survival transfer pan-cancer, Uno C-index
- system: Differential gene expression, survival transfer TCGA to CPTAC, Uno C-index
- system: Differential gene expression, held-out trials OS hazard ratio
- system: Differential gene expression, held-out trials PFS hazard ratio
- system: DGE, held-out trials OS Uno C-index, largest training pool
- system: Differential gene expression, held-out trials immunotherapy response AUROC
How to cite
Differential gene expression signature (Ladon report). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/method/ladon-20261115-method-dge-signature/
Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence